PHILADELPHIA, PA (November 30, 2012)--Fox Chase Cancer Center will host the Third International Inflammatory Breast Cancer Conference on December 1-2, 2012, at the Sofitel Philadelphia (120 South 17th Street, Philadelphia).
The conference will focus on educating healthcare professionals and breast cancer advocates about inflammatory breast cancer (IBC)--a rare and very aggressive form of the disease that accounts for 1 to 5 percent of all breast cancers.
The driving force behind this unique international conference is the collaboration between co-director's Massimo Cristofanilli, MD, Professor of Medicine at Fox Chase's Department of Medical Oncology, and Kenneth van Golen, PhD, Associate Professor in the Department of Biological Sciences at the University of Delaware. Cristofanilli's long-standing expertise in treating patients with inflammatory breast cancer, along with van Golen's well-established laboratory research on the disease makes them an ideal team to lead this conference.
The conference will commence with an opening ceremony on Saturday, December 1, 2012, at 5:00 p.m. ET. Presentations at the conference will focus on the following topics:
- MYC and Cancer: Evolving Concepts in Tumor Metabolism
- Epidemiology of IBC: New Risk Factors
- Breaking News: IBC Research Update
- Nurse Allied Health Professionals and Advocates Educational Session
- Evolving IBC Treatments: From Bench to Bedside
- Locoregional Therapies: Unanswered Questions
- Tissue Laboratory and Imaging: Detection, Discovery, Monitoring
- Roundtable Discussion: Lessons Learned and Beyond
Committee members for the 2012 Inflammatory Breast Cancer Conference, include: Pam Alizadeh, RN, Onc NP, MS, AOCN, CBCN, MD Anderson Cancer Center; Professor Francois Bertucci, MD, PhD, Institu Paoli-Calmettes; Melissa Bondy, PhD, Baylor College of Medicine; Patti Bradfield, Inflammatory Breast Cancer Foundation DBA and Erase IBC Foundation; Bernadette Ciukurescu, BSN, RN-BC, Fox Chase Cancer Center; Gayathri Devi, PhD, Duke University; Luc Y. Dirix, MD, Sint-Augustinus Hospital; Valerie Fraser, IBC Survivor/Research Advocate, Michigan Breast Cancer Coalition; Julia Goplerud, BSJ, MA, Fox Chase Cancer Center; Paul H. Levine, MD, George Washington University School of Public Health and Health Services; Ginny Mason, RN, BSN, Inflammatory Breast Cancer Research Foundation; Bonnie Miller, RN, BSN, OCN, FAAMA, Fox Chase Cancer Center; Margaret O'Grady, RN, MSN, OCN, FAAMA, Fox Chase Cancer Center; Fredika M. Robertson, PhD, MD Anderson Cancer Center; Kathy Smith, CMP, CCMEP, Fox Chase Cancer Center; Amr Soliman, MD, PhD, University of Nebraska Medical Center; Kathy Truesdale, AS, BA, Fox Chase Cancer Center; Naoto T. Ueno, MD, PhD, FACP, MD Anderson Cancer Center; Prof. Steven Van Laere, PhD, Sint-Augustinus Hospital; Peter B. Vermeulen, MD, PhD, Sint-Augustinus Hospital; Patrice Viens, MD, Institu Paoli-Calmettes; Kendra V. Woods, PhD, MD Anderson Cancer Center.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).